About

Dermatomyositis is a long-term autoimmune disease that causes a distinctive skin rash and progressive muscle weakness, which can severely limit movement and daily activities. Brepocitinib is an oral drug designed to block two key enzymes inside immune cells, TYK2 and JAK1, which are involved in sending inflammatory signals. By quieting this overactive signaling, the drug may reduce the skin and muscle inflammation that drives the disease's debilitating symptoms.